Comparing of MacroGenics Inc. (MGNX) and BioDelivery Sciences International Inc. (NASDAQ:BDSI)

We are comparing MacroGenics Inc. (NASDAQ:MGNX) and BioDelivery Sciences International Inc. (NASDAQ:BDSI) on their risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation. They both are Biotechnology companies, competing one another.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
MacroGenics Inc. 60.12M 15.52 171.45M -0.30 0.00
BioDelivery Sciences International Inc. 55.64M 6.34 46.37M -0.93 0.00

We can see in table 1 the earnings per share (EPS), top-line revenue and valuation of MacroGenics Inc. and BioDelivery Sciences International Inc.

Profitability

Table 2 shows MacroGenics Inc. and BioDelivery Sciences International Inc.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
MacroGenics Inc. -285.18% -63.2% -49%
BioDelivery Sciences International Inc. -83.34% -256.9% -55.9%

Risk and Volatility

A 3.07 beta means MacroGenics Inc.’s volatility is 207.00% more than Standard & Poor’s 500’s volatility. Competitively, BioDelivery Sciences International Inc. is 55.00% less volatile than Standard & Poor’s 500, because of the 0.45 beta.

Liquidity

The current Quick Ratio of MacroGenics Inc. is 4.5 while its Current Ratio is 4.5. Meanwhile, BioDelivery Sciences International Inc. has a Current Ratio of 3 while its Quick Ratio is 2.8. MacroGenics Inc. is better positioned to pay off its short-term and long-term debts than BioDelivery Sciences International Inc.

Analyst Ratings

The following table given below contains the ratings and recommendations for MacroGenics Inc. and BioDelivery Sciences International Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
MacroGenics Inc. 1 2 2 2.40
BioDelivery Sciences International Inc. 0 0 4 3.00

$24 is MacroGenics Inc.’s average target price while its potential upside is 25.46%. BioDelivery Sciences International Inc. on the other hand boasts of a $7.5 average target price and a 50.60% potential upside. The data from earlier shows that analysts view suggest that BioDelivery Sciences International Inc. seems more appealing than MacroGenics Inc.

Insider and Institutional Ownership

MacroGenics Inc. and BioDelivery Sciences International Inc. has shares owned by institutional investors as follows: 79.4% and 58.1%. Insiders owned 0.8% of MacroGenics Inc. shares. Comparatively, 4.7% are BioDelivery Sciences International Inc.’s share owned by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
MacroGenics Inc. -6.81% 72.63% 15.78% -7.15% -25.08% 59.45%
BioDelivery Sciences International Inc. -3.96% 4.98% 38.57% 65.81% 115.56% 31.08%

For the past year MacroGenics Inc.’s stock price has bigger growth than BioDelivery Sciences International Inc.

Summary

MacroGenics Inc. beats BioDelivery Sciences International Inc. on 7 of the 12 factors.

MacroGenics, Inc., a biopharmaceutical company, focuses on the discovery and development of antibody-based therapeutics for the treatment of cancer primarily by modulating the human immune system, as well as various autoimmune disorders and infectious diseases in the United States. The companyÂ’s advanced clinical product candidate is Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets human epidermal growth factor receptor 2-expressing tumors, such as various breast and gastroesophageal cancers. It also develops Enoblituzumab, a monoclonal antibody, which is in Phase 1 clinical trial as monotherapy in multiple solid tumor types, as well as in combination therapy with either an anti-PD-1 antibody or an anti-CTLA-4 antibody; Flotetuzumab, a DART molecule that targets CD123 and CD3; MGD007, a DART molecule, which targets glycoprotein A33 and CD3; Duvortuxizumab, a DART molecule that targets both CD19 and CD3; MGD009, a molecule in its B7-H3 franchise; MGA012, a monoclonal antibody, which targets PD-1; MGD013, a DART molecule that enables the co-blockade with a single recombinant agent of two immune checkpoint molecules; and MGC018, a B7-H3 antibody-drug conjugate. In addition, the companyÂ’s products include MGD010, a DART molecule designed to address limitations of existing B cell-targeted therapies by binding to the CD32B and CD79B proteins found on human B cells; Teplizumab, an anti-CD3 monoclonal antibody to treat type 1 diabetes; and MGD014, a DART molecule that targets human immunodeficiency virus, or HIV-infected cells, and CD3-expressing T cells. It has collaboration and license agreements with Janssen Biotech, Inc.; Les Laboratoires Servier and Institut de Recherches Servier; Boehringer Ingelheim GmbH; Pfizer, Inc.; and Green Cross Corp. MacroGenics, Inc. was founded in 2000 and is headquartered in Rockville, Maryland.

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive (BEMA) drug delivery technology, which consists of a small, erodible polymer film for application to the buccal mucosa. It offers ONSOLIS, a fentanyl buccal soluble film to treat breakthrough pain in opioid patients with cancer; BUNAVAIL, a buprenorphine and naloxone buccal film for the treatment of opioid dependence; and BELBUCA, a buprenorphine buccal film for the treatment of chronic pain. The company also develops Buprenorphine Depot Injection, an injectable microparticle formulation of buprenorphine for the treatment of opioid dependence and chronic pain. It has a licensing and development agreement with Endo Pharmaceuticals, Inc.; Evonik Corporation; Collegium Pharmaceutical, Inc.; and Meda AB. BioDelivery Sciences International, Inc. was founded in 1997 and is headquartered in Raleigh, North Carolina.